Why Are People Talking About Investing in Fresenius Medical Care (FMS)?

By Chris Stiles • Friday, January 27 12:02 • Permanent Link

Fresenius Medical Care AG marked a 3.6% change today, compared to 0.76% for the S&P 500. Is it a good value at today's price of $18.7? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally.
Fresenius Medical Care AG belongs to the Healthcare sector, which has an average price to earnings (P/E) ratio of 13.21 and an average price to book (P/B) of 4.07
The company's P/B ratio is 0.9
Fresenius Medical Care AG has a trailing 12 month Price to Earnings (P/E) ratio of 13.2 based on its trailing 12 month price to earnings (EPS) of $1.42 per share
Its forward P/E ratio is 7.8, based on its forward earnings per share (EPS) of $2.4
FMS has a Price to Earnings Growth (PEG) ratio of 6.95, which shows the company is overvalued when we factor growth into the price to earnings calculus.
Over the last four years, Fresenius Medical Care AG has averaged free cash flows of $2,086,157,000.00, which on average grew 36.0%
FMS's gross profit margins have averaged 30.2 % over the last four years and during this time they had a growth rate of -3.3 % and a coefficient of variability of 4.1 %.
Fresenius Medical Care AG has moved -46.7% over the last year compared to -8.4% for the S&P 500 -- a difference of -38.3%
FMS has an average analyst rating of underperform and is -7.03% away from its mean target price of $20.12 per share

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.